Indian Immunologicals

Indian Immunologicals Limited (IIL) is an Indian biopharmaceutical company headquartered in Hyderabad, Telangana, and operating as a subsidiary of the National Dairy Development Board. Established in 1982, the company was created to support the development and manufacture of vaccines and biological products relevant to public health, livestock production, and veterinary medicine in India. Its activities span human health, animal health, vaccine research, biological manufacturing, and international supply. The company has played a significant role in India's vaccine supply infrastructure. It is identified as a major supplier of diphtheria, pertussis and tetanus vaccines, tetanus toxoid, and hepatitis B vaccines for India's Universal Immunization Programme. Its human-health portfolio also includes rabies, hepatitis A, measles, measles-rubella, and other vaccine products. IIL's Human Biologicals Institute division was established in 1999 to manufacture modern tissue-culture anti-rabies vaccine for human use. The company's Ooty facility in Tamil Nadu was established at the request of the Government of India to help replace older nerve-tissue rabies vaccines with safer tissue-culture technology. Commercial production at the facility began in phases from 2006. IIL operates three vaccine-related manufacturing facilities in India. The Gachibowli facility in Hyderabad is associated with vaccine production, the Karakapatla facility near Hyderabad manufactures animal-health formulations and human vaccines, and the Ooty facility focuses exclusively on the human anti-rabies product Abhayrab. The company also has an overseas subsidiary, Pristine Biologicals Limited in New Zealand, which produces serum used in vaccine manufacturing. Animal health is a core part of IIL's identity. The company produces veterinary vaccines and animal-health formulations and is described as a leading Indian supplier of veterinary biologicals and a major participant in the country's animal-health market. Its portfolio covers livestock, poultry, companion animals, and aquatic health. IIL introduced Cysvax, described as the world's first vaccine against porcine cysticercosis, and is identified as India's only producer of companion-animal vaccines. It has also pursued fish-vaccine development with the Indian Council of Agricultural Research's Central Institute of Brackishwater Aquaculture. Research and development activities have extended beyond established vaccine products. IIL has worked with the Indian Council of Medical Research on development of a Zika vaccine, pursued dengue-related vaccine research, and worked on a bivalent human monoclonal antibody intended for rabies treatment. During the COVID-19 pandemic, the company led a collaboration with Griffith University in Australia to investigate a live-attenuated SARS-CoV-2 vaccine using codon-deoptimization technology. It also collaborated on development of a needle-free intranasal COVID-19 vaccine. The company expanded its human-vaccine offering with Havisure, described as India's first indigenously developed hepatitis A vaccine. Havisure is available in adult and pediatric dose formulations. In November 2023, IIL launched Mabella, a live-attenuated measles and rubella vaccine developed in partnership with Vietnam's Polyvac Institute. The launch took place during celebrations connected with the 25th anniversary of the Human Biologicals Institute in Ooty. IIL exports products to more than 50 countries, with established or developing business across the Middle East, Asia, Africa, CIS countries, and parts of Central and Latin America. Its positioning combines domestic vaccine manufacturing, public-immunization supply, veterinary biologicals, and research aimed at products suited to emerging-market health needs. The company remains active, although detailed current financial, leadership, and ownership information is not established in the supplied reference material.

Indian Immunologicals Limited was established in 1982 by the National Dairy Development Board, reflecting an Indian public-development approach to building domestic biological and vaccine capacity. From its beginning, the company operated at the intersection of public health, livestock development, and agricultural productivity. Its products were intended not only for human immunization but also for prevention of animal disease, an important area for India's dairy, farming, and companion-animal sectors. The company developed into a manufacturer of both human and veterinary vaccines. Its animal-health activities include vaccines and formulations for livestock, poultry, companion animals, and aquatic species. IIL became associated with veterinary biologicals in India and introduced Cysvax, described as the first vaccine against porcine cysticercosis. It also established a position in companion-animal immunization and pursued fish-health research through collaboration with the Indian Council of Agricultural Research's Central Institute of Brackishwater Aquaculture. Human biologicals became a distinct area of activity through the creation of the Human Biologicals Institute in 1999. The division was established to manufacture modern tissue-culture anti-rabies vaccine at Ooty in Tamil Nadu. The Ooty facility had been set up at the specific request of the Government of India to assist the transition away from older nerve-tissue rabies vaccines. Commercial production began in phases from September 2006, and the facility became associated with Abhayrab, a Vero-cell-culture vaccine for human rabies. The plant supplies a substantial portion of the requirements connected with India's public immunization system. IIL's Indian manufacturing network includes the Gachibowli facility in Hyderabad, the Karakapatla facility near Hyderabad, and the Ooty facility. Gachibowli is associated with vaccine production, while Karakapatla produces animal-health formulations and human vaccines. Ooty is dedicated to human anti-rabies vaccine production. The company also operates through Pristine Biologicals Limited in New Zealand, which produces serum used in vaccine manufacturing. IIL became a major supplier of DPT, tetanus toxoid, and hepatitis B vaccines to India's Universal Immunization Programme. This role linked the company to large-scale government immunization demand and reinforced its emphasis on products with broad public-health application. Its human-health portfolio expanded to include rabies, hepatitis A, measles, measles-rubella, and other bacterial and viral vaccines. The company has also pursued research partnerships and new biological technologies. It signed an agreement with the Indian Council of Medical Research for development of a Zika vaccine and investigated dengue-related vaccine opportunities. In rabies, it worked on a bivalent human monoclonal antibody intended for treatment rather than prevention. During the COVID-19 period, IIL led a collaboration with Griffith University of Australia on a live-attenuated SARS-CoV-2 vaccine using codon-deoptimization technology. It also participated in work on a needle-free intranasal COVID-19 vaccine. In product expansion, IIL introduced Havisure, described in the supplied reference material as India's first indigenously developed hepatitis A vaccine. The product is offered in adult and pediatric dose formats. On 25 November 2023, the company launched Mabella, a live-attenuated measles and rubella vaccine developed with Vietnam's Polyvac Institute. The launch formed part of celebrations for the 25th anniversary of the Human Biologicals Institute in Ooty. Internationally, IIL exports to more than 50 countries. Its stated geographic focus includes the Middle East, Asia, Africa, CIS countries, and expanding activity in Central and Latin America. The company's history therefore combines government-linked domestic vaccine manufacturing, animal-health innovation, public-program supply, international distribution, and collaborative research. The supplied references do not establish a complete current executive roster, detailed financial history, or independently verified present-day corporate strategy.

1. 2023Mabella measles and rubella vaccine launched

   IIL launched Mabella, a live-attenuated measles and rubella vaccine developed with Polyvac Institute of Vietnam.

   Source
2. 2006Ooty facility begins phased commercial production

   Commercial production at the Ooty human anti-rabies vaccine facility began in phases from September 2006.

   Source
3. 1999Human Biologicals Institute created

   IIL established the Human Biologicals Institute to manufacture modern tissue-culture anti-rabies vaccine for human use.

   Source
4. 1998Ooty anti-rabies facility established

   A facility in Ooty was established at the request of the Government of India to manufacture modern tissue-culture human anti-rabies vaccine and support the phase-out of nerve-tissue vaccine.

   Source
5. 1982Company established by the National Dairy Development Board

   Indian Immunologicals Limited was established in India under the sponsorship of the National Dairy Development Board.

   Source

A public-health-oriented Indian vaccine and biologicals manufacturer combining human immunization products, veterinary biologicals, animal-health formulations, and export operations.

• AbhayrabHuman anti-rabies vaccine

  Abhayrab is IIL's human anti-rabies vaccine manufactured using Vero-cell tissue-culture technology at the company's Ooty facility. The product represents the company's contribution to replacing older nerve-tissue rabies vaccines with a modern tissue-culture alternative and is used in human rabies prevention programs.

• HavisureHepatitis A vaccine

  Havisure is a hepatitis A vaccine introduced by Indian Immunologicals and described in the supplied reference material as India's first indigenously developed vaccine for this indication. It is offered in a 1 ml adult formulation and a 0.5 ml pediatric formulation.

• MabellaMeasles and rubella vaccine2023

  Mabella is a live-attenuated measles and rubella vaccine launched by IIL in November 2023. It was developed in partnership with Vietnam's Polyvac Institute and introduced during an anniversary event for the Human Biologicals Institute.

• CysvaxVeterinary vaccine

  Cysvax is an animal-health vaccine for porcine cysticercosis. IIL describes it as the world's first vaccine against the disease, illustrating the company's focus on livestock health and biological products beyond human medicine.

• DPT, TT and hepatitis B vaccinesHuman immunization vaccines

  IIL manufactures and supplies diphtheria, pertussis and tetanus vaccines, tetanus toxoid, and hepatitis B vaccines. These products have been supplied to India's Universal Immunization Programme and form part of the company's public-health manufacturing base.

• 2023Launch of Mabella measles and rubella vaccineProduct launch

  IIL sought to broaden its human vaccine portfolio through a measles-rubella product developed with Polyvac Institute of Vietnam.

  What changed. The company launched the live-attenuated Mabella vaccine on 25 November 2023.

  Aftermath. The launch was presented as part of the 25th-anniversary celebrations of the Human Biologicals Institute in Ooty. The supplied sources do not provide subsequent sales or market-share results.

  Source
• Expansion into collaborative vaccine researchStrategy

  IIL pursued research in emerging infectious diseases and new vaccine technologies in addition to established human and veterinary products.

  What changed. The company collaborated with ICMR on a Zika vaccine, with Griffith University on a live-attenuated SARS-CoV-2 vaccine, and on a needle-free intranasal COVID-19 vaccine approach.

  Aftermath. The supplied references confirm the collaborations but do not establish final approvals, commercialization, or clinical outcomes.

  Source

• 2023Indian Immunologicals launches Mabella measles and rubella vaccine

  IIL launched Mabella, a live-attenuated measles and rubella vaccine developed with Vietnam's Polyvac Institute. The launch was associated with the 25th anniversary of the company's Human Biologicals Institute division in Ooty.

  Product launch
  Source
• Indian Immunologicals introduces indigenous hepatitis A vaccine Havisure

  IIL introduced Havisure, described in the reference material as India's first indigenously developed hepatitis A vaccine, in adult and pediatric dose formats.

  Product launch
  Source
• Indian Immunologicals collaborates on Zika vaccine development

  IIL and the Indian Council of Medical Research entered an agreement concerning development of a Zika vaccine.

  Other
  Source
• Indian Immunologicals works with Griffith University on live-attenuated COVID-19 vaccine

  IIL led a cross-continental research collaboration with Griffith University in Australia to investigate a live-attenuated SARS-CoV-2 vaccine using codon-deoptimization technology.

  Other
  Source
• Indian Immunologicals collaborates on a needle-free intranasal COVID-19 vaccine

  The company participated in development work on an intranasal, needle-free COVID-19 vaccine approach.

  Other
  Source
• Indian Immunologicals advances fish-vaccine development with ICAR-CIBA

  IIL entered a collaboration with the Indian Council of Agricultural Research's Central Institute of Brackishwater Aquaculture to advance vaccines for fish health.

  Other
  Source

1. Indian Immunologicals Limited
2. Indian Immunologicals Limited official website